We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Generic drugmakers, antitrust economists and a public-interest law firm that defends free enterprise all supported Impax in amicus briefs filed in a federal appeals court, arguing that the Federal Trade Commission erred in its ruling that Impax’s 2010 settlement with Endo Pharmaceuticals was anticompetitive. Read More
Purdue Pharma and the Sackler family have until Nov. 6 to try to convince states to halt litigation against them for six months to allow the company’s bankruptcy to go ahead. Read More
The Congressional Budget Office (CBO) says the Lower Drug Costs Now Act of 2019 (H.R. 3) recently unveiled by House Speaker Nancy Pelosi could cut Medicare costs by $345 billion between 2023 and 2029. Read More
The Institute for Clinical and Economic Review (ICER) released an updated draft report on the cost-effectiveness of rheumatoid arthritis treatments but the new approach did not change the overall findings. Read More
Doctors Without Borders called on Johnson & Johnson to lower the cost of its anti-tuberculosis drug bedaquiline to $1 or less per day and allow other drugmakers to make generic versions. Read More
A New Jersey court threw out a proposed class action lawsuit against Johnson & Johnson and Actavis that accused them of causing inflated insurance premiums through their actions in the opioid crisis. Read More
The U.S. Federal Court of Appeals upheld a lower court ruling that bars Actavis’ generic of the osteoarthritis cream Pennsaid (diclofenac) two percent formulation until 2027. Read More